GenMark Diagnostics (Nasdaq: GNMK) reported earnings on May 8. Here are the numbers you need to know.

The 10-second takeaway
 For the quarter ended March 31 (Q1), GenMark Diagnostics beat expectations on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue increased significantly. GAAP loss per share contracted.

Margins grew across the board.

Revenue details
 GenMark Diagnostics tallied revenue of $11.1 million. The six analysts polled by S&P Capital IQ predicted revenue of $9.5 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $2.2 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 EPS came in at -$0.13. The four earnings estimates compiled by S&P Capital IQ anticipated -$0.17 per share. GAAP EPS were -$0.13 for Q1 compared to -$0.28 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
 For the quarter, gross margin was 54.7%, much better than the prior-year quarter. Operating margin was -38.1%, much better than the prior-year quarter. Net margin was -37.6%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
 Next quarter's average estimate for revenue is $6.6 million. On the bottom line, the average EPS estimate is -$0.23.

Next year's average estimate for revenue is $35.7 million. The average EPS estimate is -$0.79.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 11 members out of 15 rating the stock outperform, and four members rating it underperform. Among seven CAPS All-Star picks (recommendations by the highest-ranked CAPS members), three give GenMark Diagnostics a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GenMark Diagnostics is buy, with an average price target of $13.50.

Is GenMark Diagnostics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.